The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Open accessPublished version of a preprint
Abstract
The CRISPR-Cas9 system is a powerful tool for genome editing, which allows the precise modification of specific DNA sequences. Many efforts are underway to use the CRISPR-Cas9 system to therapeutically correct human genetic diseases 1-6. The most widely used orthologs of Cas9 are derived from Staphylococcus aureus and Streptococcus pyogenes 5,7. Given that these two bacterial species infect the human population at high frequencies 8,9, we hypothesized that humans may harbor preexisting adaptive immune responses to the Cas9 orthologs derived from these bacterial species, SaCas9 (S. aureus) and SpCas9 (S. pyogenes). By probing human serum for the presence of anti-Cas9 antibodies using an enzyme-linked immunosorbent assay, we detected antibodies against both SaCas9 and SpCas9 in 78% and 58% of donors, respectively. We also found anti-SaCas9 T cells in 78% and anti-SpCas9 T cells in 67% of donors, which demonstrates a high prevalence of antigen-specific T cells against both orthologs. We confirmed that these T cells were Cas9-specific by demonstrating a Cas9-specific cytokine response following isolation, expansion, and antigen restimulation. Together, these data demonstrate that there are preexisting humoral and cell-mediated adaptive immune responses to Cas9 in humans, a finding that should be taken into account as the CRISPR-Cas9 system moves toward clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, long-term expression of genome editing molecules may expose patients to undesired off-target editing or immune reactions 66,67 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-existing Cas9 antibodies and reactive T-cells have been detected in humans exposed to pathogenic bacteria harboring CRISPR systems, although it is unknown whether these are present at concentrations sufficient to trigger an immune response to the genome editing enzymes 66,104 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it is unknown whether these are present at concentrations sufficient to trigger an immune response to the genome editing enzymes 66,104 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other factors affecting clinical applications of genome editing include the immunogenicity of bacterially-derived editing proteins, the potential for pre-existing antibodies against CRISPR components to cause inflammation and the unknown long-term safety and stability of genome editing outcomes.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Another consideration for CRISPR/Cas9-based systems for retinal gene editing is the potential for a heightened adaptive immune response given the bacterial origin of the Cas9 enzyme and high prevalence of pre-existing immunity (Charlesworth et al., 2019).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Charlesworth et al., 2019
In the citing paper
“A study involving 125 healthy adult human blood donors in the USA with a median age of 43 reported pre-existing anti-SaCas9 antibodies and anti-SpCas9 antibodies in 78% and 58% of the total samples, respectively.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [24]
In the citing paper
“Among the tested donors, 78% had SaCas9-specific T-cells and 67% were positive for SpCas9-specific T-cells.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [24]
In the citing paper
“While there are discrepancies regarding the exact prevalence of these antibodies in humans, a majority of the general population may exhibit preexisting α-Cas93.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“Furthermore, a high prevalence of preexisting cellular immunity against Cas9 (Cas9-reactive T-cells) has also been identified2–4.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“multiple groups have reported high frequencies (>60% of patients) of Cas9 reactive T-cells in humans2–4.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“This may explain the lower raw ELISA A450 values we observed compared with previous work (Table 1)3.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“CRISPR-Cas9 is a promising therapeutic tool that allows genetic target-specific cleavage and editing (111).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [111]
In the citing paper
“One concern is that the prevalence of anti-SaCas9 antibodies and T-cell in humans are reported to be 78% (111).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,018
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Pukelsheim, F. (1994) · The American Statistician · doi:10.1080/00031305.1994.10476030 · Cited by 1,072
Cited by
Sorted by citations
Items 301–400 of 1,000
CRISPR-Cas systems of lactic acid bacteria and applications in food science
Cui, Y., & Qu, X. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108323 · Cited by 37
Repurposing CRISPR-Cas13 systems for robust mRNA trans-splicing
Fiflis, D. N., Rey, N. A., Venugopal-Lavanya, H., Sewell, B., Mitchell-Dick, A., Clements, K. N., Milo, S., Benkert, A. R., Rosales, A., Fergione, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46172-4 · Cited by 36
mRNA and gene editing: Late breaking therapies in liver diseases
Zabaleta, N., Torella, L., Weber, N. D., & González‐Aseguinolaza, G. (2022) · Hepatology · doi:10.1002/hep.32441 · Cited by 39
Gene Editing Technologies to Target HBV cccDNA
Martínez, M. G., Smekalova, E. M., Combe, E., Gregoire, F. M., Zoulim, F., & Testoni, B. (2022) · Viruses · doi:10.3390/v14122654 · Cited by 37
The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Hu, X., Zhang, B., Li, X., Li, M., Wang, Y., Dan, H., Zhou, J., Wei, Y., Ge, K., Li, P., et al. (2022) · Eye · doi:10.1038/s41433-022-02169-1 · Cited by 37
Rouatbi, N., Walters, A. A., Costa, P. M., Qin, Y., Liam‐Or, R., Grant, V., Pollard, S. M., Wang, J. T.-W., & Al‐Jamal, K. T. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.019 · Cited by 36
Packaged delivery of CRISPR–Cas9 ribonucleoproteins accelerates genome editing
Karp, H., Zoltek, M., Wasko, K. M., Vazquez, A. L., Brim, J. I., Ngo, W., Schepartz, A., & Doudna, J. A. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf105 · Cited by 37
The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy
Bengtsson, N. E., Tasfaout, H., & Chamberlain, J. S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.065 · Cited by 36
Saber, M. A., Biswas, P., Dey, D., Kaium, M. A., Islam, M. A., Tripty, M. I. A., Rahman, M. H., Rahaman, T. I., Biswas, M. Y., Paul, P., et al. (2021) · Processes · doi:10.3390/pr10010016 · Cited by 37
CRISPR-Cas system: from diagnostic tool to potential antiviral treatment
Rajan, A., Shrivastava, S., Janhawi, Kumar, A., Singh, A. K., & Arora, P. K. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12135-2 · Cited by 36
Schwartz, J. L., Jones, K. L., & Yeo, G. W.-M. (2020) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1841726 · Cited by 36
Zheng, R., Fang, X., Chen, X., Huang, Y., Xu, G., He, L., Li, Y., Niu, X., Yang, L., Wang, L., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.261 · Cited by 34
Himič, V., & Davies, K. E. (2021) · European Journal of Human Genetics · doi:10.1038/s41431-021-00811-2 · Cited by 36
Stojković, M., Han, D., Jeong, M., Stojković, P., & Stanković, K. M. (2021) · Stem Cells · doi:10.1002/stem.3353 · Cited by 34
Using CRISPR to understand and manipulate gene regulation
Akıncı, E., Hamilton, M. C., Khowpinitchai, B., & Sherwood, R. I. (2021) · Development · doi:10.1242/dev.182667 · Cited by 36
Immune-based therapies in cardiovascular and metabolic diseases: past, present and future
Murphy, A. J., & Febbraio, M. A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00580-5 · Cited by 35
Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy
Bandara, R. A., Chen, Z. R., & Hu, J. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00662-w · Cited by 35
Nanomedicine for advanced cancer immunotherapy
Diep, Y. N., Kim, T. J., Cho, H., & Lee, L. P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.004 · Cited by 35
Gene editing for dyslipidemias: New tools to “cut” lipids
Stankov, S. G., & Cuchel, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.010 · Cited by 34
Liver directed adeno‐associated viral vectors to treat metabolic disease
Chuecos, M. A., & Lagor, W. R. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12637 · Cited by 34
Khan, M. S., Qureshi, N., Khan, R., Son, Y., & Maqbool, T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1578138 · Cited by 37
Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy
Abaza, T., Mohamed, E., & Zaky, M. Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02939-3 · Cited by 35
The Many Faces of Gene Regulation in Cancer: A Computational Oncogenomics Outlook
Lemus, E. H., Reyes-Gopar, H., Enríquez, J. E., & Ochoa, S. (2019) · Genes · doi:10.3390/genes10110865 · Cited by 33
The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer
Ji, J., Xu, M., Qian, T., Zhu, S., Jiang, F., Liu, Z.-X., Xu, W., Zhou, J., & Xiao, M. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05685-z · Cited by 33
HIV-1 cure strategies: why CRISPR?
Atkins, A., Allen, A. G., Dampier, W., Haddad, E. K., Nonnemacher, M. R., & Wigdahl, B. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865302 · Cited by 33
Pre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview
Rouatbi, N., McGlynn, T., & Al‐Jamal, K. T. (2022) · Biomaterials Science · doi:10.1039/d1bm01452h · Cited by 33
Zhang, Y., Li, H. Z., Nishiyama, T., McAnally, J., Sanchez‐Ortiz, E., Huang, J. H., Mammen, P. P. A., Bassel‐Duby, R., & Olson, E. N. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.024 · Cited by 34
Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20065-8 · Cited by 32
Integrated epigenetic and genetic programming of primary human T cells
Goudy, L., Ha, A. S., Borah, A. A., Umhoefer, J. M., Chow, L., Tran, C., Winters, A., Talbot, A., Hernandez, R., Li, Z., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02856-w · Cited by 38
Targeting corneal inflammation by gene therapy: Emerging strategies for keratitis
Torrecilla, J., del Pozo‐Rodríguez, A., Vicente-Pascual, M., Solinís, M. Á., & Rodríguez‐Gascón, A. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.07.006 · Cited by 32
CRISPR Interference–Potential Application in Retinal Disease
Peddle, C. F., Fry, L. E., McClements, M. E., & MacLaren, R. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072329 · Cited by 33
Regulatory Considerations for Clinical Trial Applications with CRISPR-Based Medicinal Products
Anliker, B., Childs, L. H., Rau, J., Renner, M., Schüle, S., Schuessler‐Lenz, M., & Sebe, A. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0148 · Cited by 33
CRISPR and cardiovascular diseases
Musunuru, K. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac048 · Cited by 36
Kaur, S., Alley, S. C., Szapacs, M., Wilson, A., Ciccimaro, E., Su, D., Henderson, N., Chen, L., Garofolo, F., Hengel, S. M., et al. (2022) · Bioanalysis · doi:10.4155/bio-2022-0078 · Cited by 32
Self-citationChen, G., Wei, T., Yang, H., Li, G., & Li, H. (2022) · Cells · doi:10.3390/cells11192964 · Cited by 33
Harnessing CRISPR to combat human viral infections
Buhr, H., & Lebbink, R. J. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.06.002 · Cited by 33
Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment
Li, M., Chen, F., Yang, Q., Tang, Q., Xiao, Z., Tong, X., Zhang, Y., Lei, L., & Li, S. (2024) · Biomaterials Research · doi:10.34133/bmr.0023 · Cited by 32
Robust genome and cell engineering via in vitro and in situ circularized RNAs
Tong, M., Palmer, N. D., Dailamy, A., Kumar, A., Khaliq, H., Han, S., Finburgh, E. N., Wing, M. K., Hong, C., Xiang, Y., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01245-z · Cited by 32
Youssef, E. M., Weddle, K., Zimmerman, L., & Palmer, D. (2025) · Drug Safety · doi:10.1007/s40264-025-01596-9 · Cited by 31
Disruptive Technology: CRISPR/Cas-Based Tools and Approaches
Patsali, P., Kleanthous, M., & Lederer, C. W. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00391-4 · Cited by 31
Use of anti-CRISPR protein AcrIIA4 as a capture ligand for CRISPR/Cas9 detection
Johnston, R. K., Seamon, K. J., Saada, E. A., Podlevsky, J. D., Branda, S. S., Timlin, J. A., & Harper, J. C. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111361 · Cited by 31
Evaluating the probability of CRISPR‐based gene drive contaminating another species
Courtier‐Orgogozo, V., Danchin, A., Gouyon, P., & Boëte, C. (2020) · Evolutionary Applications · doi:10.1111/eva.12939 · Cited by 33
Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies
Demirci, S., Leonard, A. K., & Tisdale, J. F. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa088 · Cited by 32
Gene therapy for inherited metabolic diseases
Yılmaz, B. Ş., Gurung, S., Perocheau, D. P. B., Counsell, J. R., & Baruteau, J. (2020) · PubMed Central · doi:10.34763/jmotherandchild.20202402si.2004.000009 · Cited by 31
Genome and base editing for genetic hearing loss
Niggemann, P., György, B., & Chen, Z. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107958 · Cited by 32
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 32
The intricate pathogenicity of Group A Streptococcus : A comprehensive update
Bergsten, H., & Nizet, V. (2024) · Virulence · doi:10.1080/21505594.2024.2412745 · Cited by 30
Tang, S., Chen, X., Tong, X., & Zhu, L. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.112724 · Cited by 31
Gene and Base Editing as a Therapeutic Option for Cystic Fibrosis—Learning from Other Diseases
Mention, K., Santos, L., & Harrison, P. T. (2019) · Genes · doi:10.3390/genes10050387 · Cited by 30
Qiu, M., Glass, Z., & Xu, Q. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b00783 · Cited by 30
Mani, S., Jindal, D., & Singh, M. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220328142427 · Cited by 30
Evolution of CRISPR-associated endonucleases as inferred from resurrected proteins
Alonso-Lerma, B., Jabalera, Y., Samperio, S., Morin, M., Fernández, A., Hille, L. T., Silverstein, R. A., Quesada-Ganuza, A., Reifs, A., Fernández-Peñalver, S., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-022-01265-y · Cited by 31
Engineering a New Generation of Gene Editors: Integrating Synthetic Biology and AI Innovations
Chia, B. S., Seah, S., Wang, B., Shen, K., Srivastava, D., & Chew, W. L. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00686 · Cited by 31
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 30
Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges
Ghiaccio, V., Chappell, M., Rivella, S., & Breda, L. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00383-4 · Cited by 29
Botto, C., Dalkara, D., & El-Amraoui, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.737632 · Cited by 30
Meng, H., Nan, M., Li, Y., Ding, Y., Yin, Y., & Zhang, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148412 · Cited by 31
Using CRISPR to enhance T cell effector function for therapeutic applications
Heeren, J. J. F. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100049 · Cited by 31
Investigation of Cas9 Antibodies in the Human Eye
Toral, M. A., Charlesworth, C. T., Ng, B., Chemudupati, T., Homma, S., Nakauchi, H., Bassuk, A. G., Porteus, M. H., & Mahajan, V. B. (2022) · Nature Communications · doi:10.1038/s41467-022-28674-1 · Cited by 28
Self-citationThe potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption
Yao, Z. Q., Schank, M., Zhao, J., Gazzar, M. E., Wang, L., Zhang, Y., Hill, A. C., Banik, P., Pyburn, J. S., & Moorman, J. P. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1467449 · Cited by 28
CRISPR-based therapeutic genome editing for inherited blood disorders
Levesque, S., & Bauer, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01236-y · Cited by 31
Exploring CRISPR-Cas: The transformative impact of gene editing in molecular biology
Pandey, V. P., Sharma, S., & Pokharel, Y. R. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102717 · Cited by 29
Trinucleotide repeat instability during double-strand break repair: from mechanisms to gene therapy
Mosbach, V., Poggi, L., & Richard, G. (2018) · Current Genetics · doi:10.1007/s00294-018-0865-1 · Cited by 28
New Technologies To Enhance In Vivo Reprogramming for Regenerative Medicine
Larouche, J. A., & Aguilar, C. A. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.11.003 · Cited by 28
Ginocchio, V. M., Ferla, R., Auricchio, A., & Brunetti‐Pierri, N. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.151 · Cited by 29
Applications of CRISPR technologies in transplantation
Kuscu, C., Kuscu, C., Bajwa, A., Eason, J. D., Maluf, D. G., & Mas, V. R. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16095 · Cited by 28
In Utero Gene Therapy: Progress and Challenges
Bose, S. K., Menon, P. V., & Peranteau, W. H. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.05.007 · Cited by 29
Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4+ T-cells
Simhadri, V. L., Hopkins, L., McGill, J. R., Duke, B. R., Mukherjee, S., Zhang, K., & Sauna, Z. E. (2021) · Nature Communications · doi:10.1038/s41467-021-25414-9 · Cited by 29
Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms
Tian, S., Liu, Y., Appleton, E., Wang, H., Church, G. M., & Dong, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110476 · Cited by 30
Genome Editing and Cardiac Arrhythmias
Moore, O. M., Ho, K. S., Copeland, J. S., Parthasarathy, V., & Wehrens, X. H. T. (2023) · Cells · doi:10.3390/cells12101363 · Cited by 29
Kempthorne, L., Vaizoglu, D., Cammack, A. J., Carcolé, M., Roberts, M. J., Mikheenko, A., Fisher, A., Suklai, P., Muralidharan, B., Kroll, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55550-x · Cited by 27
Epigenome editing based treatment: Progresses and challenges
Yuan, L., Xiong, Y., Zhang, Y., Gu, S., & Lei, Y. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.047 · Cited by 30
CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedside
Humbert, O., Samuelson, C., & Kiem, H. (2020) · British Journal of Haematology · doi:10.1111/bjh.16807 · Cited by 27
CRISPR/Cas based gene editing: marking a new era in medical science
Prasad, K. M., George, A., Ravi, N. S., & Mohankumar, K. M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06479-7 · Cited by 27
Immunity and Viral Infections: Modulating Antiviral Response via CRISPR–Cas Systems
Brezgin, S., Kostyusheva, A., Олеговна, Б. Е., Volchkova, E. V., Gegechkori, V., Gordeychuk, I. V., Glebe, D., Kostyushev, D. S., & Chulanov, V. (2021) · Viruses · doi:10.3390/v13071373 · Cited by 27
Immunoresponse to Gene-Modified Hematopoietic Stem Cells
Drysdale, C. M., Tisdale, J. F., & Uchida, N. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.010 · Cited by 28
Engineering guide RNA to reduce the off-target effects of CRISPR
Wu, J., & Yin, H. (2019) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.003 · Cited by 28
Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine
Dai, X., Blancafort, P., Wang, P., Sgro, A., Thompson, E. W., & Ostrikov, K. (2020) · Advanced Science · doi:10.1002/advs.201902552 · Cited by 28
Xie, R., Wang, Y., & Gong, S. (2021) · Biomaterials Science · doi:10.1039/d1bm00558h · Cited by 26
Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads
Leandro, K., Rufino‐Ramos, D., Breyne, K., Ianni, E. D., Lopes, S., Nobre, R. J., Kleinstiver, B. P., Perdigão, P. R. L., Breakefield, X. O., & de Almeida, L. P. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115346 · Cited by 27
Farzanehpour, M., Miri, A., Alvanegh, A. G., & Gouvarchinghaleh, H. E. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115555 · Cited by 27
Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1
Marsh, S., Hanson, B., Wood, M. J. A., Varela, M. A., & Roberts, T. C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.005 · Cited by 29
Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy
Vuelta, E., García‐Tuñón, I., Hernández‐Carabias, P., Méndez, L., & Sánchez‐Martín, M. (2021) · Biology · doi:10.3390/biology10020118 · Cited by 27
Godbole, N., Quinn, A., Carrión, F., Pelosi, E., & Salomón, C. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.10.002 · Cited by 25
Engineering Cas9: next generation of genomic editors
Kovalev, M. A., Davletshin, A. I., & Karpov, D. S. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-024-13056-y · Cited by 29
Xiao, S., Wan, C., Zhou, D., Zhu, H., Bao, Y., Ji, X., Muwanguzi, K. S., & Han, Z. (2024) · Physics of Fluids · doi:10.1063/5.0188331 · Cited by 25
Yang, X., Bui, T. A., Mei, H., Aksoy, Y. A., Deng, F., Hutvágner, G., & Deng, W. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202402630 · Cited by 28
Tian, Y., Liu, R., Xian, W.-D., Xiong, M., Xiao, M., & Li, W. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.01.079 · Cited by 25
Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease
Baker, C. M., & Hayden, M. S. (2020) · F1000Research · doi:10.12688/f1000research.23185.1 · Cited by 26
Gallego, C., Gonçalves, M. A. F. V., & Wijnholds, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00838 · Cited by 26
Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases
Schreurs, J., Sacchetto, C., Colpaert, R. M. W., Vitiello, L., Rampazzo, A., & Calore, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010985 · Cited by 25
CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells
Chung, J. E., Magis, W., Vu, J. T., Heo, S., Wartiovaara, K., Walters, M. C., Kurita, R., Nakamura, Y., Boffelli, D., Martin, D. I. K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0208237 · Cited by 25
CRISPR for Neuromuscular Disorders: Gene Editing and Beyond
Young, C. S., Pyle, A. D., & Spencer, M. J. (2019) · Physiology · doi:10.1152/physiol.00012.2019 · Cited by 25
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
Zhong, C., He, S., Huang, Y., Yan, J., Wang, J., Liu, W., Fang, J., & Ren, F. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.10.029 · Cited by 24
Moitra, P., Skrodzki, D., Molinaro, M., Gunaseelan, N., Sar, D., Aditya, T., Dahal, D., Ray, P., & Pan, D. (2024) · ACS Nano · doi:10.1021/acsnano.4c01400 · Cited by 24
Synthetic Biology Speeds Up Drug Target Discovery
Xie, Y., Yang, Y.-F., He, Y., Wang, X., Zhang, P., Li, H., & Liang, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00119 · Cited by 24
Hu, M., Cherkaoui, I., Misra, S., & Rutter, G. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.576632 · Cited by 24
Paßreiter, A., Thomas, A., Grogna, N., Delahaut, P., & Thevis, M. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04445 · Cited by 24
The CRISPR revolution and its potential impact on global health security
Watters, K. E., Kirkpatrick, J., Palmer, M. J., & Koblentz, G. D. (2021) · Pathogens and Global Health · doi:10.1080/20477724.2021.1880202 · Cited by 25
Metadata
- Authors
- Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., Behlke, M. A., Dejene, B., Cieniewicz, B., Romano, R., Lesch, B. J., Gomez-Ospina, N., Mantri, S., Pavel-Dinu, M., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford Medicine (US)
- Integrated DNA Technologies (United States) (US)
- Corresponding author
- Weinberg, Kenneth I.
- Porteus, Matthew H.
- ORCID
- Charlesworth, Carsten T.
- Dever, Daniel P.
- Camarena, Joab
- Lemgart, Viktor T.
- Cromer, M. Kyle
- Vakulskas, Christopher A.
- Collingwood, Michael A.
- Zhang, Liyang
- Bode, Nicole M.
- Behlke, Mark A.
- Dejene, Beruh
- Cieniewicz, Brandon
- Romano, Rosa
- Lesch, Benjamin J.
- Gomez-Ospina, Natalia
- Mantri, Sruthi
- Pavel-Dinu, Mara
- Weinberg, Kenneth I.
- Porteus, Matthew H.
- Venue
- Nature Medicine
- Published
- 2019-01-28
- Volume
- 25
- Issue
- 2
- Pages
- 249-254
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC7199589
- OpenAlex
- W2949380898
- Cited by
- 1,093
- References
- 48
- Citations by year
- 2026: 130 · 2025: 128 · 2024: 132 · 2023: 111 · 2022: 125 · 2021: 166 · 2020: 131 · 2019: 110
- FWCI
- 44.16
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nd)
- Funders
- Amon G. Carter Foundation
- National Institutes of Health (5r01ai120766-02)
- National Institute of General Medical Sciences (T32GM119995)
- National Institute of Allergy and Infectious Diseases (R01-AI120766)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, SaCas9, SpCas9, Staphylococcus aureus, Streptococcus pyogenes, humoral immune response, cell-mediated immunity, genome editing safety
- MeSH terms
- CRISPR-Associated Protein 9, Adult, Cell Separation, Female, Humans, Male, T-Lymphocytes, Adaptive Immunity, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
